AlphAIAlphAI — Financial news for AI agents
quiverquant.com$ARWR

ARROWHEAD PHARMACEUTICALS ($ARWR) Releases Q4 2026 Earnings

Arrowhead Pharmaceuticals ($ARWR) reported Q4 2026 earnings of -$3.04 per share, missing estimates by $1.42, and revenue of $37.79M, missing estimates by $19.17M. Insiders sold shares, while hedge funds had mixed activity. Analysts set price targets, with a median of $90.0.

Original reporting
quiverquant.com
Published Nov 12, 2026, 10:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 6:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ARROWHEAD PHARMACEUTICALS ($ARWR) Releases Q4 2026 Earnings — source image
Source · quiverquant.com
Decision brief

The 30-second read

$ARWRBearishMed
01

Why it matters

The miss may prompt short sellers and cause the stock to decline in after‑hours trading.

02

Market read

Earnings miss for a micro‑cap biotech; potential short‑term price decline.

03

What to watch

Insider sales and hedge fund reductions could amplify the negative reaction.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Arrowhead Pharmaceuticals (ARWR) released its Q4 2026 results, showing a significant earnings and revenue shortfall.

Company-level read

Ticker impact

$ARWRBearishHigh confidence
Context

Q4 2026 earnings miss on both EPS (-$3.04 vs -$1.62) and revenue ($37.79M vs $56.96M) disclosed for the first time.

Expected impact

likely downward pressure as the market prices in the earnings shortfall

Evidence & confidence

Both earnings per share and revenue fell short of estimates, a material negative surprise for a micro‑cap biotech.

Market effects

Sector

Biotech sector may see modest pullback as earnings miss highlights execution risk.

Regional

US small‑cap biotech investors may adjust exposure.

Global

Limited to investors tracking micro‑cap biotech earnings.

Counterpoint

What could challenge this read

Some investors may view the miss as a buying opportunity if the company has pipeline upside.

Key entities

  • Company
    Arrowhead Pharmaceuticals

    US‑listed biotech reporting Q4 2026 earnings.

Read at source← All news

StoryArrowhead Pharmaceuticals reports FY2026 loss, REDEMPLO growth and plans SHTG launch

Also covered by

4 outlets

Related articles

$ARWRMed

Stifel cuts Arrowhead Pharma stock price target on Tryngolza launch

Stifel reduced its price target for Arrowhead Pharmaceuticals (ARWR) to $96 from $104, citing weaker-than-expected Tryngolza launch results. The stock has fallen 19% in a week, trading at $47.15. Despite this, Arrowhead and partner Ionis maintain confidence in peak sales targets. The company reported a wider loss for fiscal 2026, but revenue of $450.8 million exceeded expectations, driven by REDEMPLO launch momentum.

investing.com
$ARWRHighAI 8/10

Key facts: Arrowhead FY2026 Loss; Positive sHTG Data; REDEMPLO Launch

Arrowhead Pharmaceuticals (ARWR) reported FY2026 revenue of $450.8M, down from $829.4M, and a net loss of $724.2M. The company has $1.193B in cash and securities. Positive Phase 3 results for sHTG were announced, with a potential U.S. launch in Q2 2027. REDEMPLO for FCS was launched, and interim Phase 1/2a data for ARO-DIMER-PA showed reductions in various cholesterol and lipid levels. The average 12-month price target is $106.75, with 14 of 15 analysts rating it Buy.

tradingview.com
$ARWRHighAI 8/10

Arrowhead (ARWR) Q4 2026 Earnings Call Transcript

Arrowhead (ARWR) reported progress in its REDEMPLO drug's market penetration, with 950 new patient prescriptions and 860 prescribers as of late. The company aims for a U.S. launch in sHTG in Q2 2027, expecting FDA review. Positive clinical data shows significant triglyceride reductions and pancreatitis risk reduction. ARWR projects $3B-$4B in annual U.S. sales for REDEMPLO in sHTG. The drug is also approved in Germany and the U.K.

finance.yahoo.com
$ARWRHighAI 8/10

Arrowhead Pharmaceuticals Q4 Earnings Call Highlights

Arrowhead Pharmaceuticals reported Q4 earnings, highlighting increased prescriptions for its drugs and potential future sales. The company expects $3B-$4B in annual U.S. sales for REDEMPLO if approved for SHTG. Operating expenses rose to $1.16B, but cash reserves increased to $1.2B. Arrowhead plans to track key metrics for an SHTG launch and has upcoming pipeline milestones in 2027.

finance.yahoo.com
$ARWRHighAI 8/10

ARWR Q4 FY2026 earnings call — BigGo Finance

Arrowhead Pharmaceuticals (ARWR) reported a net loss of $724.2 million for FY2026, down from $1.6 million in FY2025, due to a one-time expense and absence of prior-year collaboration revenue. Revenue was $450.8 million, down from $829.4 million. REDEMPLO (plozasiran) generated $6.6 million in product revenue. The company is preparing for a potential U.S. launch of REDEMPLO for severe hypertriglyceridemia (SHTG) in Q2 2027. Cash position was nearly $1.2 billion as of September 30, 2026.

finance.biggo.com
$ARWRMedAI 8/10

[Arrowhead Pharmaceuticals Q4 2026 Earnings Call] Arrowhead Posts $724M Net Loss as REDEMPLO Revenue Hits $6.6M; Flags $3B-$4B SHTG Opportunity and Q2 2027 Launch

Arrowhead Pharmaceuticals reported a fiscal 2026 net loss of $724.2M, down from $1.6M in 2025, with revenue at $450.8M, a 45.6% decrease. REDEMPLO (plozasiran) generated $6.6M in net product revenue. The company aims for a Q2 2027 launch of its SHTG indication, targeting $3B-$4B in annual sales. Management expects growth despite challenges in prescription conversion and payer coverage.

finance.biggo.com